Impact on cortisol and antidepressant efficacy of quetiapine and escitalopram in depression

详细信息    查看全文

• 作者：Nina Sarubin ; Caroline Nothdurfter ; Christian Schmotz ; Anna-Maria Wimmer ; Julia Trummer ; Martin Lieb ; Manfred Uhr ; Thomas C. Baghai ; Thomas C. Wetter ; Markus B眉hner ; Rainer Rupprecht ; Cornelius Sch眉le
• 关键词：Major depression ; Escitalopram ; Quetiapine ; HPA system
• 刊名：Psychoneuroendocrinology
• 出版年：January, 2014
• 年：2014
• 卷：39
• 期：Complete
• 页码：141-151
• 全文大小：967 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Summary

Background

In this study, the impact of quetiapine fumarate extended release (QXR) and escitalopram (ESC) on HPA axis activity was investigated in depressed patients in relationship to antidepressant efficacy.

Methods

In a randomized, open-label 5-week trial 60 inpatients suffering from major depression (DSM-IV criteria) were treated for 5 weeks with either QXR (300 mg/day) or ESC (10 mg/day). The dexamethasone/CRH (DEX/CRH) test was performed before treatment, after 1, and after 5 weeks of treatment. Cortisol (COR) AUC values were used to assess HPA axis function. The Hamilton Depression Rating Scale was used weekly to estimate antidepressant efficacy.

Results

QXR and ESC showed comparable antidepressant effects but strongly differed in their impact on HPA axis activity. In the QXR group, a marked inhibition of COR AUC levels was observed which was most pronounced after one week of treatment but showed a partial re-increase after 5 weeks of treatment. In contrast, ESC transiently stimulated COR AUC values (week 1) whereas COR AUC levels at week 0 and week 5 were comparable. COR improvement at week 1 (defined as COR peak value reduction between DEX/CRH test 1 and 2) was significantly associated with better clinical outcome.

Conclusion

Apparently, different effects on HPA axis activity reflect distinct pharmacoendocrinological properties of psychotropic drugs.